Eli Lilly and Company News - April 2026
Eli Lilly and Company Q1 2026 Earnings Preview: What Analysts Expect on April 30, 2026
For the first quarter of 2026, analysts anticipate Eli Lilly and Company to report consensus revenue of approximately $17.78 billion and adjusted earnings of...
Eli Lilly signs $2.25 billion Profluent deal, targeting AI gene editing
Eli Lilly partnered with Profluent on April 28, 2026, to develop AI-driven genetic medicines. The collaboration carries a potential total value of $2.25...
Lilly's New Obesity Pill Launches Tomorrow — But Can It Justify a $935 Stock Price in a Price War With Novo?
Shares shifted as Eli Lilly secured FDA approval on April 1 for its once-daily weight-loss pill, the first oral obesity drug patients can take at any time...
Eli Lilly Wins FDA Approval for Foundayo, a Flexible Obesity Pill
The FDA approved Eli Lilly’s once-daily weight-loss pill, Foundayo (orforglipron), on April 1, 2026. This drug is the first oral GLP-1 for weight management...